Brian Dorsey

Pernix Therapeutics Holdings, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It focuses on therapeutics for diseases on central nervous system, neurology, pain, and psychiatry. Its products include treatment of migraine pain and inflammation, insomnia, and depressive disorder. It distributes products through the following brands: Treximet, Silenor, and Zohydro ER with BeadTek. The company was founded in 1996 and is headquartered in Morristown, NJ.

Septum Solutions LLC operates as a biotechnology firm. The company is headquartered in Colleyville, TX.

Neurana Pharmaceuticals, Inc. engages in a biotechnology industry. It focused on the development of drugs to treat neuromuscular disorders. The company was founded in 2013 and is headquartered in San Diego, CA.

Forge Therapeutics, Inc. manufactures pharmaceutical products. It is a biotechnology company developing novel medicines by combining bio-inorganic with medicinal chemistry to target metalloproteins. The company was founded by Zachary A. Zimmerman, Seth Cohen and David Puerta and is headquartered in San Diego, CA.

Magnasci Ventures (Magnasci) is a venture capital firm. The firm is headquartered in Houston, Texas.

Moterum Technologies, Inc. develops medical products. It offers products for stroke, traumatic brain injury, and spinal injury. The company was founded in 2017 and is headquartered in Seneca, SC.

ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA.

Blacksmith Medicines, Inc. is a pharmaceutical company based in San Diego, CA and has subsidiaries in the United States. Blacksmith Medicines is focused on developing medicines that target metal-dependent enzymes found in human physiology. The company's platform combines a focused library of metal-binding pharmacophores with proprietary computational modeling approaches to rapidly and rationally design small molecule inhibitors that interact with key metal ions in the enzymes active site. The company recognized a large unmet need for new chemical matter and innovative approaches to drug this important class of enzymes. The company was founded by Zachary A. Zimmerman and has been led by him as the CEO since incorporation.